| 46975-9 |
oxyMORphone.free |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
oxyMORphone Free [Mass/volume] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
46975-9 |
|
Confirm |
|
|
Both |
|
|
|
0 |
oxyMORphone Free Ur Cfm-mCnc |
|
|
|
N |
|
14-Hydroxydihydromorphinone; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; FR; GCMS; LC/MS/MS; Level; Mass concentration; Non-protein bound; Numorphan; Numorphone; Opana; oxyMORphone Free; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.7 |
2.19 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 46976-7 |
Benzodiazepines |
PrThr |
Ser/Plas |
Pt |
Ord |
Screen |
|
ACTIVE |
Benzodiazepines [Presence] in Serum or Plasma by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
46976-7 |
|
Screen |
|
|
Both |
|
|
|
0 |
Benzodiaz SerPl Ql Scn |
|
|
|
N |
|
Benz; Benzodiaz; Benzodiazepine; DRUG/TOXICOLOGY; Drugs; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 46977-5 |
Benzodiazepines |
MCnc |
Ser/Plas |
Pt |
Qn |
Confirm |
|
ACTIVE |
Benzodiazepines [Mass/volume] in Serum or Plasma by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
46977-5 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Benzodiaz SerPl Cfm-mCnc |
|
|
|
N |
|
Benz; Benzodiaz; Benzodiazepine; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.19 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 46978-3 |
Salicylates |
MCnc |
Ser/Plas |
Pt |
Qn |
Confirm |
|
ACTIVE |
Salicylates [Mass/volume] in Serum or Plasma by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
46978-3 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Salicylates SerPl Cfm-mCnc |
|
|
|
N |
|
2-Hydroxybenzoate; 2-Hydroxybenzoic Acid; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; o-Hydroxybenzoate; o-Hydroxybenzoic Acid; ortho-Hydroxybenzoate; ortho-Hydroxybenzoic Acid; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Sali; Salicilates; Salicylate; Salicylic acid; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.19 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 46979-1 |
Flurazepam |
MCnc |
Ser/Plas |
Pt |
Qn |
Confirm |
|
ACTIVE |
Flurazepam [Mass/volume] in Serum or Plasma by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
46979-1 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Flurazepam SerPl Cfm-mCnc |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Dalmane; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.19 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 4698-7 |
HLA-A33(19) |
PrThr |
Bld/Tiss |
Pt |
Ord |
|
|
ACTIVE |
HLA-A33(19) [Presence] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4698-7 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-A33(19) Ql |
|
|
|
|
|
Blood; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld' to 'Bld/Tiss' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 46980-9 |
N-desalkylflurazepam |
MCnc |
Ser/Plas |
Pt |
Qn |
Confirm |
|
ACTIVE |
N-desalkylflurazepam [Mass/volume] in Serum or Plasma by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
46980-9 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Desalkylfluraz SerPl Cfm-mCnc |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Desalkyfluraz; Desalkylfluraz; Desalkylflurazepam; DRUG/TOXICOLOGY; Drugs; Flurazepam metabolite; GCMS; LC/MS/MS; Level; Mass concentration; norfludiazepam; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.19 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 46981-7 |
Silicon |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Silicon [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
DRUG/TOX |
|
46981-7 |
|
|
|
|
Both |
|
|
|
0 |
Silicon Ur-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; SI; UA; UR; Urn |
2.73 |
2.19 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 46982-5 |
Liver kidney microsomal Ab.IgG |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Liver kidney microsomal IgG Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
<1:20 Normal |
|
|
|
|
|
SERO |
|
46982-5 |
|
IF |
|
|
Both |
|
|
|
0 |
LKM IgG Titr Ser IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; Hepatology; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Liver; Liver kidney microsome; LKM; Microsm; Microsom; Point in time; Random; Serology; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.19 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 46983-3 |
Ethanol |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Ethanol [Mass/volume] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
DRUG/TOX |
|
46983-3 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Ethanol Ur Cfm-mCnc |
|
|
|
N |
|
Alc; Alcohol; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Ethyl alcohol; EtOH; GCMS; LC/MS/MS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
2.19 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 46984-1 |
LDL 2 |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
LDL 2 [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHEM |
|
46984-1 |
|
|
|
|
Both |
|
|
|
0 |
LDL2 SerPl-mCnc |
|
|
|
N |
|
Cardio; Cardiology; Chemistry; Heart Disease; II; LDL2; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.19 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 46985-8 |
LDL 3 |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
LDL 3 [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHEM |
|
46985-8 |
|
|
|
|
Both |
|
|
|
0 |
LDL3 SerPl-mCnc |
|
|
|
N |
|
Cardio; Cardiology; Chemistry; Heart Disease; III; LDL3; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.19 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 46986-6 |
Cholesterol.in VLDL 3 |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cholesterol in VLDL 3 [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHEM |
|
46986-6 |
|
|
|
|
Both |
|
|
|
0 |
VLDL3c SerPl-mCnc |
|
|
|
N |
|
Cardio; Cardiology; Chemistry; Chol; Choles; Cholest; Cholesterol total; Cholesterols; Heart Disease; III; Level; Lipid; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Very low density lipoprotein cholesterols; VLDL3c; VLDLc |
2.73 |
2.19 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 46987-4 |
Helicobacter pylori Ab.IgM |
PrThr |
Ser |
Pt |
Ord |
IA |
|
ACTIVE |
Helicobacter pylori IgM Ab [Presence] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
Negative |
|
|
|
|
|
MICRO |
|
46987-4 |
|
IA |
|
|
Both |
|
|
|
0 |
H pylori IgM Ser Ql IA |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; C pylori; Campylobacter pylori; EIA; ELFA; ELISA; Enzyme immunoassay; Gastro; Gastroenterology; GI; H pyl; H pylori; IAA; Immune globulin M; Immunoglobulin M; MEIA; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR; SUDS |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 46988-2 |
GBA gene mutations tested for |
Prid |
Bld/Tiss |
Pt |
Nom |
Molgen |
|
ACTIVE |
GBA gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
46988-2 |
|
Molgen |
|
|
Observation |
|
|
|
0 |
GBA gene Mut Tested Bld/T |
|
|
|
N |
|
Beta glucosidase gene; Blood; Gaucher disease; GBA1; GBA1 (LL); GC (SP); GCB; Gene mut tested; Genetics; GLUC; GLUC (LL); Glucocerebrosidase gene; glucosidase, beta, acid; Heredity; Heritable; Identity or presence; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Tested; Mutation; Muts; Nominal; PCR; Point in time; Random; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 46989-0 |
CFTR gene targeted mutation analysis |
Find |
Amnio fld |
Pt |
Doc |
Molgen |
|
ACTIVE |
CFTR gene targeted mutation analysis in Amniotic fluid by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
46989-0 |
|
Molgen |
|
|
Both |
|
|
|
0 |
CFTR Mut Anl Amn |
|
|
|
N |
|
ABC35; ABCC7; AF; Amn; Amn fl; Amnio; Amniotic flu; Amniotic fluid; CBAVD; CF; CFA; CFTR/MRP; Cystic fibrosis transmembrane conductance regulator; cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7); dJ760C5.1; Document; Finding; Findings; Genetics; Gyn; Gynecology; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; MRP7; Mut; Mut Anl; Mutations; OB; ObGyn; Obstetrics; PCR; Point in time; Random; TNR-CFTR |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section.; Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 4699-5 |
HLA-A34(10) |
PrThr |
Bld/Tiss^Donor |
Pt |
Ord |
|
|
ACTIVE |
HLA-A34(10) [Presence] in Donor |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4699-5 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-A34(10) Donr Ql |
|
|
|
|
|
Blood; Donr; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld^donor' to 'Bld/Tiss^donor' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 46990-8 |
ASPA gene targeted mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
ASPA gene targeted mutation analysis in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
46990-8 |
|
Molgen |
|
|
Both |
|
|
|
0 |
ASPA gene Mut Anl Bld/T |
|
|
|
N |
|
ACY2; ACY-2; Aminoacylase 2; ASP; aspartoacylase; Aspartoacylase gene; Blood; Canavan disease; Document; Finding; Findings; Genetics; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; PCR; Point in time; Random; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section.; Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 46991-6 |
BLM gene targeted mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
BLM gene targeted mutation analysis in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
46991-6 |
|
Molgen |
|
|
Both |
|
|
|
0 |
BLM gene Mut Anl Bld/T |
|
|
|
N |
|
Blood; Bloom syndrome; Bloom syndrome, RecQ helicase-like; BS; Document; Finding; Findings; Genetics; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; PCR; Point in time; Random; RECQ2; RECQL2; RECQL3; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section.; Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 46992-4 |
DYS gene targeted mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
DYS gene targeted mutation analysis in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
46992-4 |
|
Molgen |
|
|
Both |
|
|
|
0 |
DYS gene Mut Anl Bld/T |
|
|
|
N |
|
Blood; Document; DYS; Dysautonomia; ELP1; Familial dysatonomia; FD; Finding; Findings; Genetics; Heredity; Heritable; IKAP; IKBKAP; IKI3; Inherited; inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; PCR; Point in time; Random; Riley-Day syndrome; Tissue; Tissue, unspecified; TOT1; WB; Whole blood; Whole blood or Tissue |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section.; Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 46993-2 |
HLA Ab panel |
- |
Ser |
Pt |
- |
|
|
ACTIVE |
HLA Ab panel - Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.HLA |
|
46993-2 |
|
|
|
|
Order |
|
|
|
0 |
HLA Ab Pnl Ser |
|
|
|
N |
|
Cytotoxic-lymphocytic antibody; Cytotoxic-lymphocytic antibody screen; Frozen lymphocyte antibody panel; HLA Ab Pnl; HLA ANTIGEN; Human Leukocyte Antigen; Lymphocyte antibody; Lymphocytotoxic antibody; Lymphocytotoxic antibody screen; Pan; Panel Reactive AB; Panel Reactive antibody; PANEL.HLA; Panl; Pnl; Point in time; PRA; Random; Serum; SR; White cell antibody screen |
2.73 |
2.19 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 46994-0 |
HLA-A+B+C Ab |
NFr |
Ser |
Pt |
Qn |
|
|
ACTIVE |
HLA-A+B+C (class I) Ab in Serum |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HLA |
|
46994-0 |
|
|
|
|
Both |
|
|
|
0 |
HLA-A+B+C Ab NFr Ser |
|
|
|
N |
|
A,B; ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; HLA ANTIGEN; HLA class I; Human Leukocyte Antigen; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Rh Blood Group System; Serum; SR; UniversalLabOrders |
2.73 |
2.19 |
|
|
|
|
|
|
|
% |
|
|
Term was deprecated in error. Status changed back to active |
0 |
| 46995-7 |
HLA-DP+DQ+DR Ab |
NFr |
Ser |
Pt |
Qn |
|
|
ACTIVE |
HLA-DP+DQ+DR (class II) Ab in Serum |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HLA |
|
46995-7 |
|
|
|
|
Both |
|
|
|
0 |
HLA-DP+DQ+DR Ab NFr Ser |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; HLA ANTIGEN; HLA class II; Human Leukocyte Antigen; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.73 |
2.19 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 46996-5 |
HLA Ab positive cells |
Num |
Ser |
Pt |
Qn |
|
|
ACTIVE |
HLA Ab positive cells [#] in Serum |
|
MIN |
DefinitionDescription |
|
|
# |
|
|
|
|
|
|
HLA |
|
46996-5 |
|
|
|
|
Observation |
|
|
|
0 |
Num HLA Ab positive cells |
|
|
|
N |
|
Cell; Cellularity; Cnt; Count; Cytotoxic-lymphocytic antibody; HLA ANTIGEN; Human Leukocyte Antigen; Lymphocyte antibody; Lymphocytotoxic antibody; Number; Panel Reactive AB; Panel Reactive antibody; Point in time; Pos; PRA; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.73 |
2.19 |
|
|
|
|
|
|
|
{#} |
|
|
|
0 |
| 46997-3 |
HLA Ab cells tested |
Num |
Ser |
Pt |
Qn |
|
|
ACTIVE |
HLA Ab cells tested [#] in Serum |
|
MIN |
DefinitionDescription |
|
|
# |
|
|
|
|
|
|
HLA |
|
46997-3 |
|
|
|
|
Observation |
|
|
|
0 |
Num HLA Ab cells tested |
|
|
|
N |
|
Cell; Cellularity; Cnt; Count; Cytotoxic-lymphocytic antibody; HLA ANTIGEN; Human Leukocyte Antigen; Lymphocyte antibody; Lymphocytotoxic antibody; Number; Panel Reactive AB; Panel Reactive antibody; Point in time; PRA; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.7 |
2.19 |
|
|
|
|
|
|
|
{#} |
|
|
|
0 |
